Nicolas Girard, MD, on the Safety Profile of Nivolumab Plus Chemotherapy in Resectable NSCLC
Nicolas Girard, MD, speaks with CancerNetwork® about the updated safety findings of nivolumab and chemotherapy in resectable non–small cell lung cancer.
Nicolas Girard, MD, on Future Research Efforts With Nivolumab and Chemotherapy in Resectable NSCLC
In a conversation with CancerNetwork®, Nicolas Girard, MD, highlighted directions of future research with nivolumab and chemotherapy in patients with resectable non–small cell lung cancer.
Nicolas Girard, MD, on the Rationale and Design of the Phase 3 CheckMate 816 Trial in Resectable NSCLC
In an interview with CancerNetwork®, Nicolas Girard, MD, discussed the rationale for assessing nivolumab and chemotherapy in resectable non–small cell lung cancer and the design of the phase 3 CheckMate 816 trial.
Nicolas Girard, MD, on EFS Findings With Nivolumab and Chemotherapy in Resectable NSCLC
Nicolas Girard, MD, highlighted key findings from the CheckMate 816 trial, examining nivolumab and chemotherapy vs chemotherapy alone in resectable non–small cell lung cancer.